相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens
Arnab Basu et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Jean-Christophe Pignon et al.
CLINICAL CANCER RESEARCH (2019)
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial
A. Ari Hakimi et al.
CANCER DISCOVERY (2019)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
Jose Lopez et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma
Kyu Seo Kim et al.
ONCOIMMUNOLOGY (2018)
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Vadim S. Koshkin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
John Cogswell et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Myeloid suppressor cells in cancer and autoimmunity
Antonio Sica et al.
JOURNAL OF AUTOIMMUNITY (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Prognostic impact of PD-1 and its ligands in renal cell carcinoma
Franziska Erlmeier et al.
MEDICAL ONCOLOGY (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy
Solene-Florence Kammerer-Jacquet et al.
TARGETED ONCOLOGY (2017)
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
Aly-Khan A. Lalani et al.
ONCOTARGET (2017)
Renal Medullary Carcinoma: Establishing Standards in Practice
Kathryn E. Beckermann et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma
Guozhu Xie et al.
CANCER BIOLOGY & THERAPY (2017)
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes
Maria I. Carlo et al.
CLINICAL GENITOURINARY CANCER (2017)
irRECIST and iRECIST: the devil is in the details
J. Le Lay et al.
ANNALS OF ONCOLOGY (2017)
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
Su-Jin Shin et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
Guillermo de Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2016)
Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations
Gabriel G. Malouf et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
The impact of hypoxia on tumor-associated macrophages
Anne-Theres Henze et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
Gabriel G. Malouf et al.
SCIENTIFIC REPORTS (2016)
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Fengju Chen et al.
CELL REPORTS (2016)
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
Guillermo de Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Benoit Beuselinck et al.
CLINICAL CANCER RESEARCH (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MiT family translocation renal cell carcinoma
Pedram Argani
SEMINARS IN DIAGNOSTIC PATHOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Collecting Duct Carcinoma Versus Renal Medullary Carcinoma An Appeal for Nosologic and Biological Clarity
Mahul B. Amin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
PD-L1 expression in nonclear-cell renal cell carcinoma
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2014)
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Caleb F. Davis et al.
CANCER CELL (2014)
Axitinib for the treatment of advanced renal cell carcinoma
Hideyuki Akaza et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Continued Increase in Incidence of Renal Cell Carcinoma, Especially in Young Patients and High Grade Disease: United States 2001 to 2010
Sallyann Coleman King et al.
JOURNAL OF UROLOGY (2014)
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
John R. Srigley et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Gabriel G. Malouf et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response
Katarzyna Franciszkiewicz et al.
CANCER RESEARCH (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Armed response: how dying cells influence T-cell functions
Thomas A. Ferguson et al.
IMMUNOLOGICAL REVIEWS (2011)
Signaling pathways in renal cell carcinoma
Gowrishankar Banumathy et al.
CANCER BIOLOGY & THERAPY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The changing pattern of kidney cancer incidence and mortality in Europe
Fabio Levi et al.
BJU INTERNATIONAL (2008)
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma
William G. Kaelin
CLINICAL CANCER RESEARCH (2007)
Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain
XH He et al.
ACTA PHARMACOLOGICA SINICA (2005)
分享论文
